MediciNova, Inc. (MNOV)
Nasdaq · Healthcare · Biotechnology
$1.76−1.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $86.4M
- 52-week range
- $1.17 – $3.90
- 52-week change
- +42.40%
- EPS (trailing)
- −$0.21
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $410K
- Net income
- $12.0M
- Operating margin
- −3242.4%
- Diluted EPS
- −$0.24
- Free cash flow
- −$9.8M
From the company’s annual report on SEC EDGAR.
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Headquarters: La Jolla, United States · 6 employees · medicinova.com